A $20 million payment cleared the moment the first healthy volunteer received a dose, which tells you exactly how much Sanofi values the second attempt at oral IRAK4 degradation. Kymera Therapeutics has opened a Phase 1 trial of KT-485 (SAR447971), its second-generation IRAK4 degrader, enrolling both adult healthy volunteers and hidradenitis suppurativa patients under a design that moves through single ascending dose and multiple ascending dose cohorts before reaching an open-label MAD arm. The trial is Sanofi-run, and Kymera is eligible for up to $975 million in total milestones if development and commercialization go the distance.

The strategic logic rests on what the first-generation molecule already demonstrated. KT-474’s Phase 1 data, published in Nature Medicine in November 2023, covered 105 healthy volunteers and 21 patients with HS or atopic dermatitis and showed measurable target engagement and a tolerable safety profile. KT-485 is described as more potent and more selective than its predecessor in preclinical work, a meaningful claim because IRAK4 sits at the junction of innate and adaptive immunity, threading signals through both the kinase activity and the scaffolding function of the myddosome complex. Degrading the protein entirely, rather than merely inhibiting its catalytic pocket, is the theoretical advantage over conventional kinase blockers: both functions go down together. Whether that translates to a cleaner clinical effect in inflammatory skin disease is precisely what this trial is designed to begin answering.

The broader degrader field acquired regulatory proof of concept on May 1, 2026, when the FDA approved vepdegestrant (Veppanu), the first PROTAC protein degrader cleared for any indication. That precedent matters for Kymera’s regulatory narrative, even though the oncology context differs entirely from the immuno-inflammatory setting KT-485 targets. Meanwhile, HS patients still depend heavily on biologics such as adalimumab, FDA-approved for moderate-to-severe disease since 2015, and an oral small molecule with a differentiated mechanism would occupy a distinct position in that treatment landscape.

The specific number to track from this trial is IRAK4 protein reduction in the HS patient cohort. Pharmacodynamic depth of degradation, not just tolerability, is what will determine whether KT-485 earns the expanded clinical program and justifies the next milestone tranche Sanofi has committed to pay.

Source link: https://www.globenewswire.com/news-release/2026/06/09/3308699/0/en/Kymera-Therapeutics-Announces-First-Participant-Dosed-in-Phase-1-Trial-of-Oral-IRAK4-Degrader-KT-485-and-Milestone-Achievement-Under-Sanofi-Collaboration.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.